NASH

Apr 14, 2025

The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more t...

Feb 14, 2025

Metabolic-associated Steatohepatitis (MASH), previously known as Non-alcoholic Steatohepatitis (NASH), is a progressive liver condition characterized by fat buildup, inflammation, and liver cell damage. With rising rates of obesity, diabetes, and metabolic syndrome worldwide, MASH is becoming a major public health ...

Oct 18, 2024

In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...

Oct 14, 2024

At present, REZDIFFRA stands as the only approved NASH drug to battle the devastating disease. This once-daily, oral THR-β agonist received a fast-track nod from the US FDA in March 2024, thanks to the impressive outcomes of the Phase III MAESTRO-NASH trial. But with one trailblazer already in the ring, the race is...

Oct 09, 2024

Nonalcoholic steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH), has rapidly become a significant contributor to liver disease in the United States. The NASH market is growing at a substantial rate, driven by the increasing prevalence of the condition. According to t...

Sep 04, 2024

Obesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Nonalcoholic Steatohepatitis is a subtype of NAFLD (Nonalcoholic Fatty Liver disease) that is characterized...

Sep 04, 2024

The prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to re...

Sep 04, 2024

Non-alcoholic steatohepatitis (NASH) has emerged as a global health concern, affecting millions of individuals worldwide. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often resulting from the accumulation of fat in the liver. In 2023, there were an estimated 42 million pr...

Sep 04, 2024

Nonalcoholic steatohepatitis is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small number of NAFLD patients possess NASH. In 2023, the United States reported the highest number of diagnosed prevalent cases of...

Sep 04, 2024

If you’ve been keeping up with our previous posts, you already have a solid understanding of nonalcoholic steatohepatitis (NASH) and its impact. We’ve previously examined the dominance of off-label therapies in the NASH therapeutics market and the challenges associated with this approach. In this post, we’ll take a...